This study aimed to determine the factors associated with the co-infection of Candida albicans and Candida glabrata. This retrospective study conducted between January 2015 and 2020 comprised 131 patients who were diagnosed with oral candidiasis. The factors associated with this condition were analyzed by univariate and multivariate logistic regression. Age and denture use were identified as significant risk factors in the univariate analysis. The multivariate logistic regression analysis revealed that denture use (odds ratio [OR], 8.44 95% confidence interval [CI], 1.99–28.3) and immunosuppressive therapy (OR, 9.20; 95% CI, 1.19–62.0) had significant effects on co-infection with the two Candida species. These findings suggest that immunosuppressive therapy using and dentures is significantly associated with oral candidiasis caused by co-infection of C. albicans and C. glabrata.

The frequency of epidermoid cysts in the maxillofacial region is relatively low. Reported: a case of a giant sublingual epidermoid cyst on the floor of the mouth. Case: 38-year-old woman. Chief complaint: oral swelling and respiratory distress. History of present illness: no special notes. Current medical history: she was aware of swelling of the floor of the mouth six months before visiting our department and was referred to our department because of increasing size. Present symptoms: at the time of examination, forced respiration and dysarthria were observed and a spherical soft elastic and well-defined mass was observed on the floor of the mouth. Due to the lesion, the tongue was displaced to the pharyngeal side and the tip of the tongue could not be confirmed. Imaging tests revealed a 65 mm × 76 mm × 54 mm well-defined mass on the mylohyoid muscle, and a dermoid or epidermoid cyst was suspected. Based on the clinical diagnosis of the cyst, the bulk of the cyst contents was reduced under general anesthesia, and the cyst was removed by intraoral surgery. The pathological diagnosis was an epidermoid cyst. For sublingual giant epidermoid cysts, removal by content reducing surgery was considered to be effective.

Delayed healing of the extraction socket is not uncommon when tooth extraction is performed on patients taking prednisolone. This study aimed to identify specific dosage of prednisolone and factors associated with delayed healing of the extraction socket in patients taking prednisolone. This single-center retrospective study included 80 patients who underwent tooth extraction under local anesthesia and were taking prednisolone orally. Patients were divided into the nondelayed healing group (n = 50) and delayed healing group (n = 30), and their background and dosage of prednisolone were compared. The dosage of prednisolone was significantly higher in the delayed healing group than in the nondelayed healing group. A receiver operating characteristics curve analysis resulted in moderate accuracy when the cutoff value was set at 8.0, with 67% sensitivity, 76% specificity, and 0.765 area under the curve. The multivariate logistic regression analysis revealed that prednisolone dosage >8.0 mg/day (odds ratio [OR], 10.8; 95% confidence interval [CI], 2.79–41.6) and osteosclerotic changes beyond the alveolar bone around the tooth to be extracted (OR, 10.3; 95% CI, 2.81–37.8) in X-ray imaging had significant effects on delayed healing. The results of this study suggested that delayed healing following tooth extractions in patients taking prednisolone was related to a dosage of 8.0 mg/day or higher and osteosclerotic changes.

Background: Ethyl loflazepate (EL) is a benzodiazepine derivative that has been reported to activate the gustatory cortex. Our department routinely uses EL as a first-line treatment for idiopathic and psychogenic taste disorders, although little has been reported in the literature with respect to patient outcomes, so we conducted a retrospective study examining its safety and efficacy. Methods: Between 2008 and 2020, 49 patients (14 males and 35 females; mean age, 62.1 years) were diagnosed with taste disorders and received EL as their only treatment for > 14 days. Severity of taste disorder was evaluated using the paper disc method by Sakai et al., and treatment efficacy was evaluated using the Visual Analog Scale, wherein patients gave subjective ratings for their symptoms (reductions by > 50% after administration of EL for 4 weeks were defined as improvements). Results: Results showed that the improvement rates for patients with idiopathic and psychogenic taste disorders were 55 and 70%, respectively. Additionally, the majority (78%) improved within 2 weeks, and side effects were mild (seven cases with drowsiness and one case with dizziness). Conclusions: We conclude that EL is an appropriate first-line medication for patients with idiopathic and psychogenic taste disorders.

Background/Objectives: A retrospective study was conducted to clarify the clinical characteristics of taste disorder cases at the Department of Oral Medicine of Hokkaido University Hospital. The subjects were 322 taste disorder patients (86 male, 236 female, average age: 66 (13.1) years, mean duration of disorder: 15.2 (20.0) months) who were treated at our department from 2007 to 2018. Methods: Associations between symptoms and classification were examined. Results: When looking at the taste symptoms, 154 cases of quantitative taste disorder were observed as taste loss, abscission, and dissociative taste disorder, and 168 cases of qualitative taste disorder were observed as spontaneous abnormal taste, dysgeusia, and maltaste. There was no relationship between sex and quantitative/qualitative taste disorders at V = 0.08. When looking at the causes of taste disorders, the majority were psychogenic, idiopathic, and oral diseases. Conclusions: Approximately 20% of taste disorders are caused by oral diseases, so it should be noted that oral diseases such as oral candidiasis and xerostomia can cause taste disorders and that many of them can be improved with oral treatment.

Background Burning mouth syndrome (BMS) is a chronic condition characterized by pain in the oral cavity. Kampo medicine is a traditional Japanese medical system that has its roots partly in ancient Chinese medicine. The purpose of this study is to evaluate the efficacy of rikkosan-a traditional Japanese herbal medicine (Kampo)-in the treatment of primary BMS. Main body A single-center retrospective study was conducted in 32 patients who were diagnosed with primary BMS and treated with rikkosan alone through gargling (2.5 g rikkosan dissolved in 50 mL hot water) three times daily. Patients were asked to evaluate their pain using a numerical rating scale (NRS) at first visit and after 1 month. One patient had stomatitis as a side effect after gargling with rikkosan, however, no side effects were observed in other patients. Overall NRS scores decreased significantly between the first visit (7.6 +/- 2.7) and the 1-month visit (5.6 +/- 2.8). Conclusions Rikkosan may be an effective treatment for primary BMS.